Feedback PLC (LON:FDBK)

Feedback PLC (LON:FDBK)


Share Price
1.18 p
Change
0 (0.00 %)
Market Cap
£4.39 m
Proactive Investors - Run By Investors For Investors

Feedback PLC

Getting the most out of every image

In an environment with ever more powerful computing possibilities, new drugs under development, and the constant need to evaluate the effectiveness of complex treatment choices, medical imaging is an integral and growing part of medical practice.

Feedback is at the forefront of medical image processing, analysis expertise and novel quantification...

EPIC: FDBK
Market: LSE:FDBK
52-week High/Low: 2.87p / 0.63p
Sector: Electronic & Electrical Equipment
Market Cap: £4.39 m
Website: www.fbk.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Feedback PLC


Feedback PLC Snapshot

In an environment with ever more powerful computing possibilities, new drugs under development, and the constant need to evaluate the effectiveness of complex treatment choices, medical imaging is an integral and growing part of medical practice.

Feedback is at the forefront of medical image processing, analysis expertise and novel quantification techniques with our Cadran and Texrad product families.

Our History

APRIL 2014 - FOCUS ON MEDICAL IMAGING
Feedback moves into the growing field of medical imaging with the conditional acquisition of Cambridge Computed Imaging Ltd and TexRAD Ltd.

2013 - AN INVESTING COMPANY
Feedback sold its time and attendance monitoring company, Feedback Data plc, and became an investing company under the AIM rules.

2012 - THE END OF AN ERA
Following a number of years of falling sales, Feedback sold its founding company, Feedback Instruments Ltd, and its US distribution business Feedback inc.

2011 - FEEDBACK DATA LAUNCHES FASTLANE
Cloud based device management over private mobile phone networks

2009 - FEEDBACK DATA UPDATES TERMINALS AND LAUNCHES MOBILE NOHMAD DEVICE
New time and attendance terminals and the first model transmitting data over the mobile phone system

2006 - LAUNCHES MICROTRAK EVOLUTION - NEXT GENERATION ACCESS CONTROL
Updated and more scaleable

1995 - FEEDBACK DATA - ENTERS ACCESS CONTROL MARKET WITH MICROTRAK PRODUCT
Managing people and doors

1993 - FEEDBACK INSTRUMENTS - LAUNCHES DISCOVERY SOFTWARE AND PROCESS CONTROL PRODUCTS
Education training packages

1991 - FEEDBACK DATA ACQUIRES SOURCE COMPUTERS LTD - ATTENDANCE MONITORING
Complimentary products and services increases scale

1983 - FEEDBACK INSTRUMENTS ACQUIRES POWERTRANS LTD - EDUCATIONAL ROBOTS
Teaching control of industrial robots

1981 - FEEDBACK PLC FLOATATION
London Stock Exchange

1970 - OPEN FIRST US OFFICE AND ESTABLISH FEEDBACK DATA LTD
Capitalising on expansion in all markets

1962 - FIRST EXPORT SALES INTO EUROPE
Pushing for growth

1958 - FOUNDED
Feedback was founded by two members of staff at Imperial College, London by Prof. John Westcott and Dr Peter Blackman, and Tom Strand to build equipment to teach the principles of engineering to university students.

 

Cadran

  • Medical imaging tools for decision support
  • Cadran Image Storage Management offers fully featured image display, review and manipulation options and enterprise archiving for clinical, non-clinical and teaching use
  • Medical images wherever and whenever you need them. Fully featured archive, robust and secure.

Cadran is produced by Cambridge Computed Imaging Ltd. CCI are specialists in providing software that helps doctors use medical images to make decisions.

Clinicians can display, review and manipulate images using in-line measurement and analysis tools to assist diagnosis and quantify treatment response.

 

For more information go to CadranISM.com

 

TexRAD

  • Stratification of clinical diagnostic images for prognosis, risk and treatment response
  • TexRAD analyses the textures in radiological scans and has the potential to assist clinicians in assessing the prognosis of patients with cancer. TexRAD analysis has been retrospectively performed on images from a wide range of conditions including colorectal, breast, lung, prostrate, oesophageal, head and neck, and renal cancers

TexRAD offers an innovative quantitative tool to clinicians researching the diagnosis, prognosis and treatment response of cancer.

TexRAD helps users analyse, detect and measure textures in medical images, revealing more information than is evident to the naked eye.

 

More information at TexRAD.com

 

Dr Alastair Riddell, Executive Chairman

Dr Riddell has over 30 years’ experience in the pharmaceutical, life science and biotech industries, with 18 years as a main board director. After 10 years directing phases 1-4 clinical trials of antibiotics, oncology and intensive care products for companies including Lederle (now Pfizer) and Centocor (now J&J), he spent five years managing sales and marketing for oncology and imaging products for Amersham International (now GE Healthcare). This led to 12 years as CEO for three UK biotech companies, Pharmagene, Paradigm Therapeutics and Stem Cell Sciences; in these roles he was the principal involved in an IPO on UK’s main list, trade sales to international companies in Japan and the USA and significant fund raising rounds. He has been Chairman of Silence Therapeutics (AIM listed) and Chairman of Definigen Ltd, a private Cambridge University spinout. He is currently on the Board of three biotechnology companies;  AzurRx Biotherapeutics, a New York based drug development company listed on NASDAQ; Cristal Therapeutics, a Netherlands based company specialising in nanoparticle medicines; and Skyline Vet Pharma, a US based private company repurposing human drugs for use in companion animals. He is also Chairman of the SWAHSN (South West Academic Health Science Network), which seeks to improve and sustain the healthcare provision in the south-west of England by linking innovation from industry, academia and the NHS. Dr Riddell is on the Remuneration committee.

Lindsay Melvin, Chief Financial Officer

Mr Melvin is a chartered accountant and brings 30 years of financial and business experience to Feedback. Most recently he was Chief Executive Officer of the Chartered Institute of Payroll Professionals (CIPP) for eight years until July 2016. CIPP was voted the UK’s best association in the 2016 Associations Excellence Awards and was also voted as one of the Sunday Times “Best 100 Not for Profit Organisations” in 2016. Previously, Mr Melvin held Director-level roles in small- to medium-sized public and private companies including Arthur Shaw & Co plc where he was Finance Director for six years. Mr Melvin started his career at Grant Thornton where he spent 11 years.

Tim Irish, Non-Executive Director

Tim is a Professor of Practice at Kings College London as well as a board member of Bournemouth University. Tim joined the board of the National Institute for Health and Care Excellence (NICE) in April 2015 and became the Senior Independent Director in May 2017. Tim has worked in the life sciences industry for thirty years. His career has spanned global health technology companies across Europe and North America, including GSK, GE and Philips the latter two in senior positions responsible for medical imaging. Tim also currently holds a number of non-executive positions in health and technology related entities.

Simon Sturge, Non-Executive Director

Mr Sturge joined Merck Healthcare in 2014 and is currently Chief Operating Officer and member of the Healthcare Executive Committee. He is an experienced healthcare executive in the UK and has built a very strong reputation not only in the biotechnology industry but also in the investment community. His experience includes eight years at Celltech, and he was the founder and CEO of RiboTargets which later reversed into Vernalis Plc. After serving as CEO of OctoPlus N.V. for two years, he became Senior Vice President of Boehringer Ingelheim’s Biopharmaceutical Business. Mr Sturge is a regular speaker at conferences including the World Economic Forum.

Significant shareholders
As at 9th May 2018, shareholders who have notified the company of shareholdings in excess of 3% are:

Shareholder No. of Shares %
T E Brown 11,689,111 4.15
T W G Charlton 69,437,408 24.66
W R Ruffler 12,597,893 4.47
University of Sussex 9,400,000 3.34
Jonathan David Selby Cranston 20,000,000 7.10

 

Get in touch

 

We operate from Bourn, just outside Cambridge.

Grange Park
Broadway
Bourn
Cambridge CB23 2TA
United Kingdom

Tel +44 (0) 1954 718072

Nominated Advisor (NOMAD):
Allenby Capital Limited
5 St Helen’s place
London
EC3A 6AB

Brokers:
Allenby Capital Limited
5 St Helen’s place
London
EC3A 6AB

Peterhouse Corporate Finance Limited
3rd Floor
New London House
15 Eldon Street
London
EC2M 7LD

Registrars:
Share Registrars Ltd
The Courtyard
17 West Street
Farnham
Surrey
GU9 7DR

Auditor:
haysmacintyre
26 Red Lion Square
London
WC1R 4AG

Bankers:
Natwest Bank
Conqueror House,
Vision Park,
Cambridge
CB24 9NL

Columns Including FDBK

VIEW ALL

Market Reports Including FDBK

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use